GLP-1受体激动剂对PCOS相关心血管疾病的影响  

Influence of GLP-1 receptor agonists on PCOS-related cardiovascular diseases

作　　者：刘雪梅[1] 詹晓蓉[1] 郭钰雪 LIU Xue-mei;ZHAN Xiao-rong;GUO Yu-xue(Department of Endocrinology,First Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,150001,China)

机构地区：[1]哈尔滨医科大学附属第一医院内分泌科,黑龙江哈尔滨150001

出　　处：《心血管康复医学杂志》2023年第3期294-297,共4页Chinese Journal of Cardiovascular Rehabilitation Medicine

基　　金：中国人群前瞻性生物样本库建设(KJZD-EW-TZ-L05)。

摘　　要：随着生活方式的改变,肥胖成为多囊卵巢综合征(PCOS)的主要危险因素。肥胖可加剧恶化PCOS患者的不良表型、生殖功能和代谢障碍,尤其是心血管疾病(CVD)风险增加。肥胖、PCOS是CVD的重要危险因素。胰高血糖素样肽-1受体激动剂(GLP-1 RA)具有独特的代谢靶点,可以同时改善肥胖、代谢障碍和生殖功能,降低CVD风险。本文就GLP-1 RA对PCOS相关CVD的影响作一综述。With change of lifestyle,obesity has become a major risk factor for polycystic ovary syndrome(PCOS).Obesity aggravates adverse phenotype,reproductive function and metabolic disorders in PCOS patients,especially increased risk of cardiovascular disease(CVD).Obesity and PCOS are important risk factors of CVD.Glucagon-like peptide-1 receptor agonists(GLP-1 RA)have unique metabolic targets that can simultaneously improve obesity,metabolic disorders and reproductive function,and reduce CVD risk.The present article makes a review on influence of GLP-1 RA on PCOS-related CVD.

关 键 词：心血管疾病 多囊卵巢综合征 胰高血糖素样肽1 

分 类 号：R54[医药卫生—心血管疾病]